{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T09:58:56Z","timestamp":1773223136620,"version":"3.50.1"},"reference-count":78,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["22K06707"],"award-info":[{"award-number":["22K06707"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Background\/Objectives: Cancer therapy-induced alopecia (CTIA) profoundly affects patients\u2019 quality of life. This study conducted a disproportionality analysis of CTIA using the FDA Adverse Event Reporting System (FAERS) database to provide an overview of drug-specific signal distributions by systematically evaluating the impact of reporter type on CTIA signal detection. Methods: FAERS data from January 2004 to September 2024 were analyzed to extract alopecia-related Preferred Terms included under the Medical Dictionary for Regulatory Activities High Level Term \u201cAlopecias.\u201d Reporting odds ratios (RORs) were calculated to assess disproportionality. A primary analysis including all reports and a stratified analysis restricted to reports submitted by healthcare professionals (HCPs) were performed. No individual case-level clinical review was conducted. Results: Approximately 90% of alopecia reports were associated with female patients, and approximately 40% of these reports were linked to breast cancer. In the disproportionality analysis including all reporters, the highest ROR [95% confidence interval (CI)] was observed for docetaxel [58.31 (57.46\u201359.17)]. In the analysis restricted to HCP reports, the highest ROR was observed for vismodegib [23.92 (21.86\u201326.17)], whereas that for docetaxel markedly decreased to 3.68 (3.48\u20133.89). For molecular targeted agents, statistically significant signals were maintained even in the HCP-restricted analysis. Conclusions: Reporter characteristics substantially influence the detection of alopecia signals, with patients amplifying signals reflecting psychological harm and HCPs amplifying signals reflecting pharmacological plausibility. These findings should be interpreted as hypothesis-generating and warrant further validation using prospective or clinical datasets.<\/jats:p>","DOI":"10.3390\/ph19030445","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T12:39:08Z","timestamp":1773146348000},"page":"445","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of Reporter Type on Signal Detection of Cancer Therapy-Induced Alopecia: A Hypothesis-Generating Study Using the FDA Adverse Event Reporting System"],"prefix":"10.3390","volume":"19","author":[{"given":"Airi","family":"Yajima","sequence":"first","affiliation":[{"name":"Department of Medical Molecular Informatics, Meiji Pharmaceutical University, 2-522-1 Noshio, Kiyose 204-8588, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5773-991X","authenticated-orcid":false,"given":"Yoshihiro","family":"Uesawa","sequence":"additional","affiliation":[{"name":"Department of Medical Molecular Informatics, Meiji Pharmaceutical University, 2-522-1 Noshio, Kiyose 204-8588, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1046\/j.1523-5394.2001.96007.x","article-title":"Psychological sequelae and alopecia among women with cancer","volume":"9","author":"McGarvey","year":"2001","journal-title":"Cancer Pract."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1136\/bmj.331.7522.951","article-title":"The psychological impact of alopecia","volume":"331","author":"Hunt","year":"2005","journal-title":"BMJ"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/pon.1245","article-title":"Chemotherapy-induced alopecia and effects on quality of life among women with breast cancer: A literature review","volume":"17","author":"Lemieux","year":"2008","journal-title":"Psychooncology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e50","DOI":"10.1016\/S1470-2045(12)70553-3","article-title":"Pathobiology of chemotherapy-induced hair loss","volume":"14","author":"Paus","year":"2013","journal-title":"Lancet Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1001\/jamadermatol.2018.0454","article-title":"Endocrine therapy-induced alopecia in patients with breast cancer","volume":"154","author":"Shapiro","year":"2018","journal-title":"JAMA Dermatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1093\/annonc\/mdv390","article-title":"Alopecia in patients treated with molecularly targeted anticancer therapies","volume":"26","author":"Belum","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s10549-018-4855-2","article-title":"Persistent major alopecia following adjuvant docetaxel for breast cancer: Incidence, characteristics, and prevention with scalp cooling","volume":"171","author":"Martin","year":"2018","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_8","first-page":"e13395","article-title":"Permanent hair loss associated with taxane chemotherapy use in breast cancer: A retrospective survey at two tertiary UK cancer centres","volume":"30","author":"Chan","year":"2021","journal-title":"Eur. J. Cancer Care"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"5709","DOI":"10.3390\/curroncol31090423","article-title":"Chemotherapy-induced alopecia by docetaxel: Prevalence, treatment and prevention","volume":"31","author":"Perez","year":"2024","journal-title":"Curr. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1001\/jamadermatol.2020.1867","article-title":"Association between ABCB1 genetic variants and persistent chemotherapy-induced alopecia in women with breast cancer","volume":"156","author":"Pita","year":"2020","journal-title":"JAMA Dermatol."},{"key":"ref_11","first-page":"199","article-title":"Approaches to management of endocrine therapy-induced alopecia in breast cancer patients","volume":"33","author":"Nguyen","year":"2025","journal-title":"Support. Care Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1634\/theoncologist.2016-0186","article-title":"Characterization and management of Hedgehog pathway inhibitor-related adverse events in patients with advanced basal cell carcinoma","volume":"21","author":"Lacouture","year":"2016","journal-title":"Oncologist"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S1470-2045(15)70100-2","article-title":"Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): A multicentre, randomised, double-blind phase 2 trial","volume":"16","author":"Migden","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.annder.2022.11.013","article-title":"Dermatologic toxicities to inhibitors of cyclin-dependent kinases CDK 4 and 6: An updated review for clinical practice","volume":"150","author":"Sibaud","year":"2023","journal-title":"Ann. Dermatol. Venereol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/S1470-2045(18)30292-4","article-title":"Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): A randomised phase 3 trial","volume":"19","author":"Tripathy","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_16","first-page":"1","article-title":"Palbociclib plus letrozole as first-line therapy in postmenopausal Asian women with metastatic breast cancer: Results from the phase III, randomized PALOMA-2 study","volume":"5","author":"Im","year":"2019","journal-title":"J. Glob. Oncol."},{"key":"ref_17","first-page":"e11031","article-title":"CDK4\/6 inhibition mitigates stem cell damage in a novel model for taxane-induced alopecia","volume":"12","author":"Purba","year":"2020","journal-title":"EMBO Mol. Med."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Cutroneo, P.M., Sartori, D., Tuccori, M., Crisafulli, S., Battini, V., Carnovale, C., Rafaniello, C., Capuano, A., Poluzzi, E., and Moretti, U. (2024). Conducting and interpreting disproportionality analyses derived from spontaneous reporting systems. Front. Drug Saf. Regul., 3.","DOI":"10.3389\/fdsfr.2023.1323057"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Petracek, J., and Fialova, M. (2023). Spontaneous reporting systems. Principles and Practice of Pharmacovigilance and Drug Safety, Springer. Chapter 10.","DOI":"10.1007\/978-3-031-51089-2_10"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.4103\/0976-500X.120955","article-title":"Limitations and obstacles of the spontaneous adverse drug reactions reporting: Two \u201cchallenging\u201d case reports","volume":"4","author":"Palleria","year":"2013","journal-title":"J. Pharmacol. Pharmacother."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1001\/jamaoncol.2015.2639","article-title":"Validity and reliability of the U.S. National Cancer Institute\u2019s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)","volume":"1","author":"Dueck","year":"2015","journal-title":"JAMA Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2147\/PROM.S256567","article-title":"Clinician and patient reporting of symptomatic adverse events in cancer clinical trials: Using CTCAE and PRO-CTCAE\u00ae to provide two distinct and complementary perspectives","volume":"13","author":"Minasian","year":"2022","journal-title":"Patient Relat. Outcome Meas."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1093\/jnci\/djab015","article-title":"Underreporting of symptomatic adverse events in phase I clinical trials","volume":"113","author":"Veitch","year":"2021","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1248\/yakushi.17-00174-4","article-title":"Adverse effect predictions based on computational toxicology techniques and large-scale databases","volume":"138","author":"Uesawa","year":"2018","journal-title":"Yakugaku Zasshi"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1001\/jamadermatol.2018.5071","article-title":"Assessment of quality of life and treatment outcomes of patients with persistent postchemotherapy alopecia","volume":"155","author":"Chan","year":"2019","journal-title":"JAMA Dermatol."},{"key":"ref_26","first-page":"E17","article-title":"Permanent alopecia in breast cancer patients: Role of taxanes and endocrine therapies","volume":"107","author":"Slaught","year":"2021","journal-title":"Cutis"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.jdcr.2023.02.021","article-title":"Hair regrowth in endocrine therapy alopecia with dutasteride treatment in a woman with estrogen-positive breast cancer","volume":"35","author":"Dubin","year":"2023","journal-title":"JAAD Case Rep."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"469","DOI":"10.5301\/tj.5000376","article-title":"Adjuvant aromatase inhibitor therapy in early breast cancer: What factors lead patients to discontinue treatment?","volume":"101","author":"Moscetti","year":"2015","journal-title":"Tumori"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s10549-013-2744-2","article-title":"Aromatase inhibitor therapy and hair loss among breast cancer survivors","volume":"142","author":"Gallicchio","year":"2013","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1634\/theoncologist.2013-0193","article-title":"Alopecia with endocrine therapies in patients with cancer","volume":"18","author":"Saggar","year":"2013","journal-title":"Oncologist"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"302","DOI":"10.5603\/ocp.100128","article-title":"Combination of chemotherapy and endocrine treatment in breast cancer\u2014Is it still a taboo?","volume":"20","author":"Wysocki","year":"2024","journal-title":"Oncol. Clin. Pract."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Zhao, Q., Nian, Z., He, Y., Lai, L., Liu, W., Huang, S., and Yang, L. (Expert Opin. Drug Saf., 2025). Toxicity spectrum of taxanes: A safety analysis from pre-marketing to post-marketing, Expert Opin. Drug Saf., in press.","DOI":"10.1080\/14740338.2025.2464080"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1002\/acr.24596","article-title":"2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis","volume":"73","author":"Fraenkel","year":"2021","journal-title":"Arthritis Care Res."},{"key":"ref_35","first-page":"1586","article-title":"Therapeutic effect of the combination of etanercept and methotrexate compared with each drug alone in patients with rheumatoid arthritis: Double-blind randomized controlled trial","volume":"343","author":"Klareskog","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1002\/acr.23999","article-title":"Low-dose methotrexate and mucocutaneous adverse events: Results of a systematic literature review and meta-analysis of randomized controlled trials","volume":"72","author":"Lalani","year":"2020","journal-title":"Arthritis Care Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1002\/1529-0131(200107)44:7<1515::AID-ART273>3.0.CO;2-7","article-title":"Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: A forty-eight week, multicenter, randomized, double-blind, placebo-controlled study","volume":"44","author":"Laan","year":"2001","journal-title":"Arthritis Rheum."},{"key":"ref_38","unstructured":"Judicial Panel on Multidistrict Litigation (JPML) (2025, December 07). IN RE: Taxotere (Docetaxel) Products Liability Litigation. MDL No. 2740. Transfer Order, Available online: https:\/\/www.jpml.uscourts.gov\/sites\/jpml\/files\/MDL-2740-Initial_Transfer-09-16.pdf."},{"key":"ref_39","unstructured":"Judicial Panel on Multidistrict Litigation (2025, December 07). MDL Statistics Report\u2014Distribution of Pending MDL Dockets by Actions Pending\u2014July 1, 2025, Available online: https:\/\/www.jpml.uscourts.gov\/sites\/jpml\/files\/Pending_MDL_Dockets_By_Actions_Pending-July-1-2025_0.pdf."},{"key":"ref_40","unstructured":"Judicial Panel on Multidistrict Litigation (2025, December 07). MDL Statistics Report\u2014Distribution of Pending MDL Dockets by District\u2014October 1, 2025, Available online: https:\/\/www.jpml.uscourts.gov\/sites\/jpml\/files\/Pending_MDL_Dockets_By_District-October-1-2025.pdf."},{"key":"ref_41","unstructured":"United States District Court, Eastern District of Louisiana (2025, December 07). MDL-2740: IN RE: Taxotere (Docetaxel) Products Liability Litigation\u2014MDL Docket Page, Available online: https:\/\/www.laed.uscourts.gov\/case-information\/mdl-mass-class-action\/taxotere."},{"key":"ref_42","unstructured":"United States District Court,  Eastern District of Louisiana (2025, December 07). Order and Reasons, IN RE: Taxotere (Docetaxel) MDL No. 16-2740; Rec. Doc. 16778, Available online: https:\/\/www.govinfo.gov\/content\/pkg\/USCOURTS-laed-2_16-md-02740\/pdf\/USCOURTS-laed-2_16-md-02740-86.pdf."},{"key":"ref_43","unstructured":"Free Law Project, and CourtListener (2025, December 07). Taxotere (Docetaxel) Products Liability Litigation, MDL No. 2740\u2014Docket. Available online: https:\/\/www.courtlistener.com\/docket\/17279738\/in-re-taxotere-docetaxel-products-liability-litigation\/."},{"key":"ref_44","unstructured":"European Medicines Agency (EMA) (2018). Spontaneous Adverse Drug Reactions\u2014Subgroup Report, EMA\/HMA. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/report\/spontaneous-adverse-drug-reactions-subgroup-report_en.pdf."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"5542","DOI":"10.1200\/JCO.2005.02.027","article-title":"Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer","volume":"23","author":"Jones","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s40264-017-0530-5","article-title":"The quality of clinical information in adverse drug reaction reports by patients and healthcare professionals: A retrospective comparative analysis","volume":"40","author":"Rolfes","year":"2017","journal-title":"Drug Saf."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/BF03261977","article-title":"Patient versus healthcare professional spontaneous adverse drug reaction reporting: A systematic review","volume":"35","author":"Inch","year":"2012","journal-title":"Drug Saf."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/bjd.13619","article-title":"Hair loss and Hedgehog inhibitors: A class effect?","volume":"173","author":"Ferguson","year":"2015","journal-title":"Br. J. Dermatol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S1470-2045(20)30536-2","article-title":"Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): A randomised, open-label, multicentre, non-inferiority, phase 3 study","volume":"22","author":"Tan","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Ventura, I., Salcedo, N.P., P\u00e9rez-Bermejo, M., P\u00e9rez-Murillo, J., Tejeda-Adell, M., Tom\u00e1s-Aguirre, F., Legidos-Garc\u00eda, M.E., and Murillo-Llorente, M.T. (2025). Pertuzumab in combination with trastuzumab and docetaxel as adjuvant doublet therapy for HER2-positive breast cancer: A systematic review. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26051908"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Yajima, A., and Uesawa, Y. (2025). A comprehensive analysis of adverse events associated with HER2 inhibitors approved for breast cancer using the FDA adverse event reporting system (FAERS). Pharmaceuticals, 18.","DOI":"10.20944\/preprints202508.0516.v1"},{"key":"ref_52","unstructured":"Genentech, Inc. (2025, December 07). Rituxan (rituximab) Injection, for Intravenous Use, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/103705s5464lbl.pdf."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"894","DOI":"10.36849\/JDD.6690","article-title":"Rituximab-induced alopecia universalis in a patient with bullous pemphigoid","volume":"21","author":"Puiu","year":"2022","journal-title":"J. Drugs Dermatol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"keaa109.005","DOI":"10.1093\/rheumatology\/keaa109.005","article-title":"Successful treatment of alopecia universalis with rituximab therapy","volume":"59","author":"Oke","year":"2020","journal-title":"Rheumatology"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Shan, G., Wang, H., Li, X., Ren, Y., and Zhang, F. (2023). Biological sex and adverse drug reactions: A review of sex differences in pharmacovigilance data. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1096366"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Brabete, J., Ehret, V., and Tricco, A.C. (2022). A sex- and gender-based analysis of adverse drug reactions: A scoping review of pharmacovigilance databases. Pharmaceuticals, 15.","DOI":"10.3390\/ph15030298"},{"key":"ref_57","first-page":"100228","article-title":"Global patterns of sex differences in adverse drug reactions: An analysis of pharmacovigilance data","volume":"15","author":"Watson","year":"2019","journal-title":"EClinicalMedicine"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"3285","DOI":"10.1007\/s00210-025-04721-8","article-title":"Biological sex differences in pharmacokinetics and adverse drug reactions","volume":"399","author":"Aljohmani","year":"2026","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/164_2023_669","article-title":"Sex differences in pharmacokinetics: Predicting adverse drug reactions from pharmacokinetic variability","volume":"Volume 282","author":"Zucker","year":"2023","journal-title":"Handbook of Experimental Pharmacology"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2165\/00003088-200342020-00001","article-title":"The influence of sex on pharmacokinetics","volume":"42","author":"Schwartz","year":"2003","journal-title":"Clin. Pharmacokinet."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.jaad.2009.06.063","article-title":"Permanent chemotherapy-induced alopecia: Case report and review of the literature","volume":"63","author":"Tallon","year":"2010","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1093\/annonc\/mds095","article-title":"Permanent scalp alopecia related to breast cancer chemotherapy by sequential fluorouracil\/epirubicin\/cyclophosphamide (FEC) and docetaxel: A prospective study of 20 patients","volume":"23","author":"Kluger","year":"2012","journal-title":"Ann. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1634\/theoncologist.2018-0184","article-title":"Permanent chemotherapy-induced alopecia in patients with breast cancer: A 3-year prospective cohort study","volume":"24","author":"Kang","year":"2019","journal-title":"Oncologist"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"54","DOI":"10.35772\/ghm.2022.01062","article-title":"Distress and impacts on daily life from appearance changes due to cancer treatment: A survey of 1,034 patients in Japan","volume":"5","author":"Nozawa","year":"2023","journal-title":"Glob. Health Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/00002820-200601000-00006","article-title":"Postmenopausal women with breast cancer: Their experiences of the chemotherapy treatment period","volume":"29","author":"Browall","year":"2006","journal-title":"Cancer Nurs."},{"key":"ref_66","unstructured":"European Organisation for Research and Treatment of Cancer (EORTC) (2024). EORTC QLQ-BR42 Module (English, Final Version), EORTC. Available online: https:\/\/www.eortc.org\/app\/uploads\/sites\/2\/2024\/04\/BR42-Module-English-FINAL.doc."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.annonc.2019.10.027","article-title":"An international update of the EORTC questionnaire for assessing quality of life in breast cancer patients: EORTC QLQ-BR45","volume":"31","author":"Cardoso","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_68","first-page":"5090","article-title":"Efficacy of scalp cooling for prevention of chemotherapy-induced alopecia: A systematic review and meta-analysis","volume":"25","author":"Shen","year":"2021","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_69","first-page":"e202303024","article-title":"Scalp cooling for the prevention of chemotherapy-induced alopecia: Systematic review and meta-analysis","volume":"97","year":"2023","journal-title":"Rev. Esp. Salud Publica"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S0190-9622(96)90500-9","article-title":"A randomized trial of minoxidil in chemotherapy-induced alopecia","volume":"35","author":"Duvic","year":"1996","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"91","DOI":"10.4103\/ijt.ijt_70_23","article-title":"Low-dose oral minoxidil in the treatment of alopecia: Evidence- and experience-based consensus statement of Indian experts","volume":"15","author":"Godse","year":"2023","journal-title":"Int. J. Trichol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s10549-024-07440-5","article-title":"Oral minoxidil for late alopecia in cancer survivors","volume":"208","author":"Kuo","year":"2024","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1080\/08858190802664594","article-title":"Look good feel better workshops: A \u201cbig lift\u201d for women with cancer","volume":"24","author":"Taggart","year":"2009","journal-title":"J. Cancer Educ."},{"key":"ref_74","first-page":"e1242","article-title":"Effects of the appearance care program for breast cancer patients receiving chemotherapy: A mixed method study","volume":"3","author":"Ikeda","year":"2020","journal-title":"Cancer Rep."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.3390\/curroncol31050189","article-title":"Beauty therapy to support psychosocial recovery from oncological care: A qualitative research on the lived experience of women with breast cancer treated with chemotherapy","volume":"31","author":"Vagnini","year":"2024","journal-title":"Curr. Oncol."},{"key":"ref_76","unstructured":"U.S. Food and Drug Administration (2025, December 05). FDA Adverse Event Reporting System (FAERS), Available online: https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-adverse-event-reporting-system-faers-database."},{"key":"ref_77","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology (2024). ATC\/DDD Index 2024, World Health Organization. Available online: https:\/\/www.whocc.no."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1081\/SAC-200040691","article-title":"Small sample confidence intervals for the odds ratio","volume":"33","author":"Lawson","year":"2004","journal-title":"Commun. Stat. Simul. Comput."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/3\/445\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T12:43:54Z","timestamp":1773146634000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/3\/445"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,10]]},"references-count":78,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["ph19030445"],"URL":"https:\/\/doi.org\/10.3390\/ph19030445","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,10]]}}}